Related references
Note: Only part of the references are listed.Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Raajit K. Rampal et al.
CLINICAL CANCER RESEARCH (2021)
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
Fabio P. S. Santos et al.
LEUKEMIA (2020)
Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice
Veronika Lysenko et al.
BLOOD ADVANCES (2020)
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
Giacomo Coltro et al.
BLOOD ADVANCES (2020)
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
Daniel A. C. Fisher et al.
LEUKEMIA (2019)
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Sabrina Cordua et al.
BLOOD (2019)
A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies
Yuanbin Song et al.
NATURE COMMUNICATIONS (2019)
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN
Lucia Mazzacurati et al.
BLOOD ADVANCES (2019)
How I treat myelofibrosis after failure of JAK inhibitors
Animesh Pardanani et al.
BLOOD (2018)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Maria Kleppe et al.
CANCER CELL (2018)
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
E. J. Duncavage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells
Hamza Celik et al.
CANCER CELL (2018)
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor et al.
CLINICAL CANCER RESEARCH (2018)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset
Sathish K. R. Padi et al.
ONCOTARGET (2017)
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML
Akihide Yoshimi et al.
BLOOD (2017)
Efficacy of ALK5 inhibition in myelofibrosis
Lanzhu Yue et al.
JCI INSIGHT (2017)
Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice
Yasuyuki Saito et al.
BLOOD (2016)
Characterization of CD34+hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms
Anna Angona et al.
LEUKEMIA RESEARCH (2016)
A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells
Andreas Reinisch et al.
NATURE MEDICINE (2016)
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Andrew L. Young et al.
NATURE COMMUNICATIONS (2016)
Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Michael C. Gundry et al.
CELL REPORTS (2016)
Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation
Katie A. Matatall et al.
CELL REPORTS (2016)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis
Ruggiero Norfo et al.
BLOOD (2014)
Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
Jeffery M. Klco et al.
CANCER CELL (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Raajit Rampal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms
Shih-Min A. Huang et al.
ONCOTARGET (2014)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion
David G. Kent et al.
PLOS BIOLOGY (2013)
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera
Ann Mullally et al.
BLOOD (2012)
Genetics of the myeloproliferative neoplasms
Omar Abdel-Wahab
CURRENT OPINION IN HEMATOLOGY (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
Omar Abdel-Wahab et al.
CANCER RESEARCH (2010)
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
M. Wunderlich et al.
LEUKEMIA (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration
FE Nicolini et al.
LEUKEMIA (2004)
Share Paper
